About: Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 07 February 2017

Attributes	Values
rdf:type	Item
description	videnskabelig artikel (da) article científic (ca) articolo scientifico (it) artigo científico (pt) bilimsel makale (tr) vedecký článok (sk) vetenskaplig artikel (sv) vědecký článek (cs) wetenschappelijk artikel (nl) wissenschaftlicher Artikel (de) научни чланак (sr) article scientifique (fr) artículu científicu espublizáu en 2017 (ast) наукова стаття, опублікована в лютому 2017 (uk) scientific article published on 07 February 2017 (en) مقالة علمية نشرت في 07 فبراير 2017 (ar)
publication date	wds:Q37657236-4478BED5-382E-45EB-BB28-EFCA13DE68F1
publication date	2017-02-07 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q37657236-0D282E92-F2B8-4F7D-AE85-C8B41AC39157
language of work or name	English
cites work	wds:Q37657236-036903B3-0D04-4C62-A232-7D527B2D05F8 wds:Q37657236-049B2039-FA66-4CE3-872D-2DF87505569B wds:Q37657236-065ABD68-D50D-41D1-B417-37AE6D4AAE24 wds:Q37657236-0F03D0E7-8B76-4F3E-8822-FAD1BA5A436A wds:Q37657236-31A8528B-8248-4F06-BFF2-6A1FB5FA4FD5 wds:Q37657236-3A601609-DD5E-4580-A1C7-8B721F06EB61 wds:Q37657236-40AE11A9-54B2-4E96-9B0E-571B23CF297A wds:Q37657236-412212FF-10C0-44A2-A982-EF1F4587E42E wds:Q37657236-4633A682-2412-44CA-8003-7EC144B8C052 wds:Q37657236-4FFC69A7-9175-4841-A7BF-8E56D5EB95DE wds:Q37657236-5C9C0AE5-CAA4-4DC1-96E5-6CB3D6FE5340 wds:Q37657236-5DDB4A76-973E-47C8-95F4-FFE987B8EE9D wds:Q37657236-757A04DD-BE5E-49E9-B90A-5EF519C96263 wds:Q37657236-80035711-20C4-4B17-93B4-25161E502C7E wds:Q37657236-8516C6D8-2A6E-4FEF-8585-FFFD55F1AA1C wds:Q37657236-89286A72-0305-48F7-8F5C-51CD72BD41A7 wds:Q37657236-8B9148B7-D2B1-48AB-B872-C260366D0A34 wds:Q37657236-8BEC5972-485E-4778-B302-B3F3E2C0C998 wds:Q37657236-962C2D76-DBCC-4985-BBB0-ECA81B65EECE wds:Q37657236-A1C0E023-06A1-4F43-9629-79E706049AF5 wds:Q37657236-A7DD8842-EA06-4C4F-B03F-1A616E5908A3 wds:Q37657236-B0742040-B6F5-42F0-97A7-43B35DC90ED5 wds:Q37657236-B62FCA48-0A4B-48AD-A494-191CFE0B63FB wds:Q37657236-D04EE46C-8EEF-46AF-8773-91508AF91A2C wds:Q37657236-DB7F8F17-8622-40F3-B710-455312C3A654 wds:Q37657236-E25CF523-A3DF-422F-B88F-82DF524C2F73 wds:Q37657236-EB64DADC-4BD9-4882-ADCA-E9B915156710 wds:Q37657236-F1B3EC57-D4B4-45F4-928B-F82B9B6A6C66 wds:Q37657236-F6D63804-F667-49A2-B56B-CB4376C95A3B wds:Q37657236-FCAF3396-5634-4BF4-B19B-BCECCEFF2C70
cites work	Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study Kidney cancer, version 3.2015. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Racial/ethnic and gender disparities in renal cell carcinoma incidence and survival Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Cancer treatment and survivorship statistics, 2012 Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies Lymphovascular invasion in clear cell renal cell carcinoma--association with disease-free and cancer-specific survival A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Prognostic factors in patients with advanced renal cell carcinoma treated with VEGF-targeted agents Risk stratification and prognostication of renal cell carcinoma Growth pattern, an important pathologic prognostic parameter for clear cell renal cell carcinoma Validation of the MSKCC and Heng risk criteria models for predicting survival in patients with metastatic renal cell carcinoma treated with sunitinib Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy Urinary collecting system invasion reflects adverse long-term outcome and is associated with simultaneous metastatic spread at the time of surgery and with multilocular dissemination during postsurgical follow-up in renal cell cancer Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma Systemic therapy for advanced renal cell carcinoma Cytokine-based therapy for metastatic renal cell cancer Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents. Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma
author name string	wds:Q37657236-46F5C05E-D993-432B-B880-84744FA835BB wds:Q37657236-4F5642B3-D6E6-4CD2-B02A-117BE31C1AE5 wds:Q37657236-5DACC81C-FB1D-437D-8C72-07193BD8AD43 wds:Q37657236-7299F352-826C-4BD0-86FA-BE6ABE910240 wds:Q37657236-7AD6BC1D-4C4F-4064-862F-13122FCF2F18 wds:Q37657236-89740A52-5707-4515-8CC0-758578113DF9 wds:Q37657236-B8378F34-604A-4858-BC05-705E81F43BF9 wds:Q37657236-CC9DE338-D5EB-41E4-8EDC-FA8CD411D0E6 wds:Q37657236-E26970CC-90F3-4384-AE89-1989F4306F91
author name string	Sang Eun Lee Tae Nam Kim Cheol Kwak Sung-Hoo Hong Tae Gyun Kwon Byung-Ho Nam Ill Young Seo Sohee Kim Kanghyon Song
rdfs:label	Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study (en)

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software